Burning Mouth Syndrome (BMS) is a chronic, idiopathic orofacial pain condition defined by a persistent burning, scalding, or tingling sensation in the oral mucosa in the absence of identifiable clinical lesions or laboratory abnormalities. The discomfort most frequently involves the anterior two-thirds of the tongue, the anterior hard palate, and the labial mucosa.
Types of Burning Mouth Syndrome
BMS is broadly classified into two forms. Primary BMS (also called idiopathic BMS) has no identifiable organic cause and is thought to involve neuropathic mechanisms, including dysfunction of peripheral small-diameter nerve fibers or alterations in central pain processing. Secondary BMS arises as a consequence of an underlying local or systemic condition and typically resolves once that condition is treated.
Common Causes and Contributing Factors
Secondary BMS may be triggered by a range of systemic and local factors. Identifying these is essential before attributing symptoms to primary BMS:
- Hormonal changes, particularly in postmenopausal women
- Nutritional deficiencies, especially iron, zinc, folate, and B-complex vitamins
- Xerostomia (dry mouth) associated with medications or Sjögren’s syndrome
- Allergic contact reactions to dental materials, flavorings, or oral hygiene products
- Psychological factors, including anxiety, depression, and chronic stress
Clinical Significance
Patients with BMS frequently report accompanying symptoms such as dysgeusia (altered or metallic taste) and subjective xerostomia, even when salivary flow rates fall within normal limits. The condition disproportionately affects middle-aged and postmenopausal women, though it can occur in any demographic. Because there are no visible mucosal changes, BMS is a diagnosis of exclusion — clinicians must rule out candidiasis, geographic tongue, contact stomatitis, and other conditions affecting the oral epithelium before confirming the diagnosis.
Management varies by type. Secondary BMS responds to treating the underlying etiology, such as correcting a nutritional deficiency or substituting an offending medication. Primary BMS management often involves low-dose clonazepam (topical or systemic), cognitive behavioral therapy, alpha-lipoic acid supplementation, and patient education on minimizing triggers such as spicy foods, alcohol-containing rinses, and sodium lauryl sulfate-containing dentifrices.
A thorough medical and pharmacologic history combined with targeted laboratory screening is the most effective first step toward identifying the cause and relieving a patient’s chronic oral discomfort.